Trial Profile
PhaseII study of erlotinib in previously treated non-small cell lung cancer (NSCLC) with wild type EGFR
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2017
Price :
$35
*
At a glance
- Drugs Erlotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 18 Oct 2017 Results presented at the 18th World Conference on Lung Cancer
- 23 Jan 2013 Status changed from recruiting to discontinued as reported by University Hospital Medical Information Network - Japan record.
- 26 Apr 2011 New trial record